New Quantitive MRI Parameters in Assessing Kidneys of Autosomal Dominant Polycystic Kidney Disease (MRI Pilot)
The purpose of this study is to establish normal Magnetic Resonance quantitative values (tissues stiffness, Apparent Diffusion Coefficient values and Blood Oxygen Level Determination values for both renal cortex and medullary tissues and total renal blood flow) for young Autosomal Dominant Polycystic Kidney Disease patients with normal renal function, and normal young adult controls without Autosomal Dominant Polycystic Kidney Disease and normal renal function.
Hypothesis: Newer Magnetic Resonance quantitative imaging parameters (tissue stiffness, Apparent Diffusion Coefficient, Blood Oxygen Level Determination levels, Magnetization Transfer and renal blood flow) will have different values in young adult ADPKD patients as compared to normal volunteers.
|Autosomal Dominant Polycystic Kidney Disease Kidney Disease|
|Study Design:||Observational Model: Case Control
Time Perspective: Retrospective
|Official Title:||Pilot and Feasibility Study: Evaluation of New Quantitative Magnetic Resonance Imaging Parameters in Assessing the Kidneys of Autosomal Dominant Polycystic Kidney Disease|
- Evaluate renal tissue stiffness [ Time Frame: baseline ]The renal parenchymal tissue stiffness is measured in kilopascals with magnetic resonance elastography sequence.
- Magnetization transfer ratio [ Time Frame: baseline ]The magnetization transfer ratio of renal tissue is measured with magnetization transfer sequence and expressed as a ratio.
- Diffusion [ Time Frame: baseline ]Diffusion is quantified as apparent diffusion coefficient (x10-3/mm2) in renal tissue is measured with intravoxel incoherent motion imaging (IVIM) sequence and diffusion tensor imaging (DTI).
- Perfusion quantified as blood flow in mL/s. [ Time Frame: baseline ]Perfusion in the renal tissue is measured with arterial spin labeling sequence and phase contrast magnetic resonance angiography.
|Study Start Date:||December 2014|
|Study Completion Date:||March 2016|
|Primary Completion Date:||March 2016 (Final data collection date for primary outcome measure)|
Please refer to this study by its ClinicalTrials.gov identifier: NCT02250287
|United States, Minnesota|
|Rochester, Minnesota, United States, 55905|
|Principal Investigator:||Sudhakar Venkatesh, MD||Mayo Clinic|